Clinical Trial Search

Primary: Change From Baseline in DBP After 8 Weeks of Treatment — -10.19; -12.38 mmHg — p=0.007

Primary: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment — -25.32; -19.32 units on a scale — p=0.124

Primary: Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks) — -2.7; -1.4 units on a scale — p=0.005

Primary: 5-year Overall Survival — 56; 56 Percent of population — p=0.49

Primary: Percentage of Treatment Responders at Month 4 — 39.3; 10.9 Percentage of Subjects

Primary: Change From Mean Part A Primary Impairment Visual Analogue Scale Score (After 6 Weeks) at the End of Four Weeks of Open-label Treatment (10 Weeks Total) — -5.41; -7.51…

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period — 4.9; 4.1 units on a scale

Primary: 28-Day All-Cause Mortality — 26.4; 24.2 percentage of participants — p=0.313

Primary: Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment — 0.026; 0.055; -0.073 Liters

Primary: Number of Participants With Any Rash Event (Including Stevens-Johnson Syndrome [SJS] and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment…

Primary: Prolonged Abstinence — 25; 28 participants

Primary: Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks) — -1.36; -0.84 units on a scale…

Primary: Death or Chronic Lung Disease — 76; 68; 62 participants

Primary: Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score. — -1.18; -0.63 units on a scale — p=0.048

Primary: Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1) — -0.035; 0.069; 0.069; 0.056 L